Earlier this summer, thousands of biopharmaceutical industry leaders gathered for the BIO International Convention in the nation’s biotech hub of Boston to discuss business deals, scientific advances and policy issues. Among those conversations, questions about the Inflation Reduction Act and its potential impact on our industry were top of mind. Just how much will policies that reduce economic incentives make it even harder to produce groundbreaking new therapies, especially for the rare disease…
